GSK's Depemokimab Receives European and Chinese Approvals, Expanding Global Access to Ultra-Long-Acting Biologic

Key Takeaways

• GSK received regulatory approvals for depemokimab from the European Commission and China’s National Medical Products Administration
• Depemokimab is the first ultra-long-acting biologic approved for therapeutic use, offering extended dosing intervals for patients
• The drug now has marketing authorization in five major global markets including the US, Japan, UK, Europe, and China

---

GSK Expands Global Reach with New Depemokimab Approvals

GSK plc has secured additional regulatory victories for its breakthrough biologic depemokimab, receiving marketing approvals from both the European Commission (EC) and China’s National Medical Products Administration (NMPA) in April 2026. These approvals significantly expand patient access to what represents the first ultra-long-acting biologic treatment in its class.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Milestone Achievement for Ultra-Long-Acting Biologics

The recent approvals build upon GSK’s existing regulatory successes, with depemokimab now authorized for marketing in five major global pharmaceutical markets: the United States, Japan, the United Kingdom, European Union, and China. This comprehensive regulatory approval portfolio positions GSK to serve patients across diverse healthcare systems worldwide.

Adimab, LLC, GSK’s collaboration partner and a leader in monoclonal and multispecific antibody discovery, congratulated GSK on achieving these regulatory milestones. The partnership leverages Adimab’s expertise in fully human antibody engineering to develop innovative therapeutic solutions.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Patient Benefits

Depemokimab’s ultra-long-acting formulation represents a significant advancement in biologic therapy, potentially reducing treatment burden through extended dosing intervals. This characteristic could improve patient compliance and quality of life while maintaining therapeutic efficacy.

The drug’s approval across major pharmaceutical markets creates substantial commercial opportunities for GSK, with combined patient populations in these regions representing billions of potential beneficiaries. The staggered approval timeline demonstrates GSK’s strategic approach to global market entry.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Future Outlook

With regulatory approvals secured in key markets, GSK can now focus on commercial launch activities, including manufacturing scale-up, distribution partnerships, and healthcare provider education. The company’s ability to navigate diverse regulatory environments successfully positions depemokimab for potential expansion into additional international markets.

---

Frequently Asked Questions

What makes depemokimab different from other biologic treatments?

Depemokimab is the first ultra-long-acting biologic approved for therapeutic use, offering extended dosing intervals that could reduce treatment frequency compared to conventional biologics.

When will depemokimab be available to patients in Europe and China?

While regulatory approval has been granted, commercial availability depends on GSK’s launch timeline, manufacturing readiness, and local market access negotiations in each region.

Which other markets has depemokimab been approved in?

Depemokimab has received marketing approvals in the United States, Japan, and the United Kingdom, in addition to the recent European Commission and Chinese NMPA approvals.

Related coverage

• Manufacturing pipeline approvals: what the evidence confirms
• EMA backs datopotamab deruxtecan, but lung cancer access remains unclear
• Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing